Associated Papers
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Wang Y et al.
Lung Cancer (amsterdam, Netherlands), 2020
Crizotinib-resistant MET mutations in gastric cancer patients are sensitive to type II tyrosine kinase inhibitors.
Shen B et al.
Future Oncology (london, England), 2019
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K et al.
Medicine, 2019
A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib.
Lin H et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
Li YQ et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2017
Select a paper to view details